Akathisia is one of the most distressing experiences a person can have, and one of the least understood by clinicians who have not seen it in benzodiazepine patients. The word itself comes from a Greek root meaning “unable to sit,” but that translation does not capture what the experience actually feels like. Patients describe a relentless internal restlessness, a sense of needing to move that cannot be relieved by movement, a feeling of being driven from inside their own skin. It can produce pacing for hours, an inability to lie still, a sense that the body is being electrified, and a level of suffering that breaks down even patients who have weathered everything else withdrawal has thrown at them.
Akathisia is not a fringe symptom of benzodiazepine withdrawal. It is one of the symptoms patients fear most, and one of the symptoms that most often goes unrecognized when patients show up in emergency rooms or psychiatric offices looking for help. Understanding what akathisia is, why it happens during benzodiazepine withdrawal, and what does and does not help is essential for patients living with it and for the clinicians trying to support them.
What Akathisia Actually Is
Akathisia is a movement disorder, but the movement is the visible part of a deeper neurological state. The patient’s nervous system has shifted into a pattern of dysregulation that produces a continuous feeling of needing to move, combined with a continuous failure of movement to provide any relief. A person with simple anxiety paces because they are anxious. A person with akathisia paces because they cannot stop, and the pacing does not help.
The internal experience is what makes akathisia so difficult to convey. Patients describe it as restlessness multiplied many times over, as agitation that has no emotional cause, as a feeling of wanting to crawl out of their own body. Sleep becomes nearly impossible because lying still is intolerable. Sitting through a meal can feel like sitting on hot coals. Even the smallest tasks become exhausting because the body is constantly in motion or constantly demanding motion.
This experience is often mistaken for severe anxiety, and the two can coexist, but they are not the same. Anxiety responds to calming inputs. Akathisia does not. A patient with akathisia will tell you that nothing they have tried touches it, and they are usually correct.
Why Benzodiazepine Withdrawal Produces Akathisia
Benzodiazepines work primarily through GABA-A receptors, the main inhibitory system in the central nervous system. Long-term benzodiazepine use leads to receptor adaptation: the system becomes less responsive to the medication and to the body’s own GABA. When the medication is reduced or removed, the inhibitory tone that was being maintained pharmacologically is no longer available. The nervous system is left in a state of relative excitation that the body has not yet reorganized to handle.
That excitation does not show up uniformly. It manifests through whichever pathways are most vulnerable in the individual patient. In some patients it is sleep that breaks down. In others it is autonomic regulation. In others it is sensory processing. And in some, the pattern of dysregulation produces akathisia. The dopaminergic and adrenergic systems are involved, the GABAergic system is involved, and the result is a motor and sensory state that resembles the akathisia produced by certain antipsychotics, even though the trigger is entirely different.
The Misdiagnosis Problem
Patients with benzodiazepine-induced akathisia are routinely misdiagnosed. Emergency room clinicians, primary care physicians, and even psychiatrists who have not specifically encountered withdrawal-related akathisia often interpret the presentation as severe anxiety, agitated depression, or a panic state. The patient describes inability to sit still, racing internal feelings, and overwhelming distress. The diagnostic conclusion is usually that the patient needs more medication for their anxiety, not less.
This misreading drives some of the worst clinical decisions made for benzodiazepine patients. A patient with akathisia from benzodiazepine withdrawal who is given a higher dose of benzodiazepine may feel briefly better and then feel worse. A patient given an antipsychotic for what is interpreted as agitation may have their akathisia made dramatically worse, because antipsychotics can produce akathisia of their own through a different mechanism. The original problem is not addressed, and the medication response often adds new layers of suffering.
Recognizing akathisia for what it is, in the context of a benzodiazepine taper or a recent reduction, changes the entire treatment approach. The problem is not anxiety. The problem is a nervous system that has been pushed past what it can compensate for.
What Standard Responses Get Wrong
Several common clinical responses to akathisia during benzodiazepine withdrawal tend to make the situation worse rather than better.
Adding antipsychotics is one of the most damaging. Quetiapine, risperidone, olanzapine, and similar medications carry their own risk of producing akathisia. For a patient already in a withdrawal-related akathisia state, adding an antipsychotic can compound the problem. The patient ends up with two overlapping akathisias driven by different mechanisms, and the second one will not resolve until the antipsychotic is removed.
Increasing or reinstating benzodiazepines often produces partial relief that does not last. The dose needed to suppress the akathisia tends to climb. Reinstatement may be the right move for some patients in some contexts, but it is not a long-term solution for akathisia.
Pushing the taper forward through severe akathisia is rarely the answer. Many patients have been told to “stay the course” when their nervous system is signaling that the rate of reduction is more than it can manage. Continuing to cut while in active akathisia tends to deepen the problem.
What Can Help
The honest answer is that no medication reliably eliminates withdrawal-related akathisia. There are interventions that sometimes reduce the intensity, and there are strategies that help the patient survive the experience until time and a stabilized nervous system bring the akathisia down.
Slowing or pausing the taper is usually the first step. Akathisia often signals that the current rate of reduction is exceeding what the nervous system can absorb. Holding at the current dose, or even returning to a slightly higher prior dose, can give the system time to settle.
Physical strategies that some patients find partial relief in include cold water on the face or hands, weighted blankets, slow rhythmic movement that the patient chooses rather than being driven into, and time outdoors with the kind of low-stimulation environment that does not amplify the sensory load. None of these is a treatment. They are tools that may help a patient endure the hours and days while the underlying state slowly improves.
Beta blockers such as propranolol are sometimes used to reduce the adrenergic component, with mixed results. Hydroxyzine is sometimes useful at the margins. For some patients, a small amount of opioid analgesia produces relief that nothing else has touched, though this is rarely a sustainable approach. The most consistent finding is that there is no consistent answer, and patients respond differently.
The Role of Time
Akathisia driven by benzodiazepine withdrawal eventually subsides, but the time course is highly variable. Some patients see improvement within days of stabilizing the taper. Others live with significant akathisia for months. A subset of patients with protracted symptoms or BIND experience akathisia as a long-term feature that gradually softens over many months or years rather than weeks.
This is why the work of recognizing akathisia early and adjusting the taper accordingly matters so much. The longer a patient remains in active akathisia, the harder the recovery process becomes. Dr. Leeds approaches akathisia as a signal that something is wrong with the rate of reduction, not as a symptom to medicate around. The most effective response is usually the one that addresses the underlying destabilization, supports the patient through the difficult window, and avoids interventions that risk making the akathisia worse.
Patients who live through severe akathisia and come out the other side describe it as one of the most difficult experiences of their lives. The fact that it improves, and that patients do recover, is a piece of information worth holding on to during the worst of it.